Back

Merck KGaA and Remepy join forces to develop combo drug-digital therapies

April 28, 2026

More like this

May 21, 2026

Remepy's hybrid Parkinson's therapy poised for phase 3

Pharmaphorum

May 20, 2026

Remepy posts strong Phase IIa results for Hybridopa

The Pharma Letter

May 20, 2026

Remepy Reports Strong Clinical Phase IIa Results for Hybridopa™, a First-in-Class Hybrid Drug for Parkinson’s Disease

Press Release